Management of men with bone metastasis over time

A new review article in issue 2 of Everyday Urology addresses the topic of bone mets, quality of life, and related factors in the management of advanced and metastatic prostate cancer over time. … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

A better way to identify risk for metastasis?

According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …

Is IL-33 expression a key to risk for prostate cancer progression and metastasis?

According to a newly published article in the journal Scientific Reports, men who lose normal expression of a protein known as interleukin-33 or IL-33 are at higher risk for recurrence of their prostate cancer within 5 years than men who do not lose the expression of this biomarker. … READ MORE …

That “rise” in the incidence of metastatic prostate cancer

Well … Don’t say we didn’t warn you. The American Cancer Society (ACS) and others are now saying that the study suggesting a rise in the incidence of metastatic prostate cancer from 2004 to 2013 has serious flaws. … READ MORE …

A first-in-human trial of actinium-225-PSMA-617

Among the more interesting developments in radiation oncology/nuclear medicine in recent years are novel therapies created by attaching radioactive isotopes to molecules (called ligands) that attach to the prostate-specific membrane antigen (PSMA). … READ MORE …

Another Sunnybrook update: risk for metastasis on active surveillance

The Sunnybrook Group from the University of Toronto in Canada have just provided us with yet another update on the outcomes of their cohort of 980 patients managed initially on active surveillance and dating back to 1996. … READ MORE …

How cancer metastasizes — a large-scale review

For those who are really interested in the slow if steady progress toward an understanding of why and how cancer cells metastasize out of the organ they are formed in (e.g., the prostate) to spread through the body (e.g., the spine, other bones, the lungs, the liver, etc.) … READ MORE …

Site of prostate cancer metastasis and length of patient survival

There has long been information suggesting that exactly where prostate cancer metastasizes to (outside of the prostate itself) is really important to how long a patient might reasonably expect to survive once metastasis is evident. This is why patients with higher-risk disease get both a bone scan and a CT scan at diagnosis. … READS MORE –

Metastases after early vs. delayed salvage radiation

Until we have the results of randomized clinical trials on the relative efficacy of early salvage radiation therapy (RT), we have to look for other clues to inform the timing of that decision. … READ MORE …

Can a regular aspirin regimen extend survival of men with prostate cancer?

Another intriguing paper to be presented this week at the Genitourinary Cancers Symposium suggests an association between regular aspirin intake and risk for lethal prostate cancer among men already diagnosed with prostate cancer. … READ MORE …

Is the Decipher test really as useful as it’s manufacturer seems to claim?

A newly published article in the journal PLoS One questions whether the Decipher® test (a 22-gene expression assay test) has actual clinical utility in helping physicians to make good decisions about the follow-up treatment of men with prostate cancer after an initial radical prostatectomy. … READ MORE …

Screening and the incidence of newly diagnosed, metastatic prostate cancer over time

Another article in this week’s issue of the New England Medical Journal is going to re-fuel the fire among those who advocate for widespread, frequent screening of men for risk of prostate cancer. … READ MORE …

The role of CT scanning in assessment of progression of men with CRPC

A newly published paper in the journal Cancer seems to be implying that every man with castration-resistant prostate cancer who progresses from non-metastatic to metastatic status (based on a bone scan or other indicators) should also be given a CT scan because of risk for soft tissue metastasis. … READ MORE … >

Newer types of whole body scanning are likely to be significantly better than older bone scans, but …

A new report in the Journal of Nuclear Medicine has suggested that it may be time to start looking seriously at whether the combined [18F]NaF/[18F]FDG PET/CT scan may be significantly better than the traditional [99m]Tc bone scan in evaluation of risk for or the actual presence of metastasis in men with prostate cancer. … READ MORE …